UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
WASHINGTON, D.C. 20549
____________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): March 8, 2016
MACROGENICS, INC.
(Exact Name of Registrant as Specified in Charter)
|
Delaware
|
001-36112
|
06-1591613
|
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission
File Number) |
(IRS Employer
Identification No.) |
|
9640 Medical Center Drive,
Rockville, Maryland
|
20850
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Registrant's telephone number, including area code: (301) 251-5172
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective March 8, 2016, MacroGenics, Inc. (the "Company") entered into an Employment Agreement with Ezio Bonvini, M.D. (the "Employment Agreement"). Dr. Bonvini is the Company's Senior Vice President, Research. The terms of the Employment Agreement were approved by the Company's Board of Directors.
The Employment Agreement provides for the payment of an annual base salary of $360,500 with an annual performance bonus target opportunity of up to 35% of his base salary. There are no family relationships between Mr. Bonvini and any director or other officer of the Company or any related party transactions involving Mr. Bonvini.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date: March 10, 2016
|
MACROGENICS, INC.
|
|
|
|
By:
|
/s/Atul Saran
Atul Saran
Senior Vice President and General Counsel
|